A bill introduced in Minnesota highlights the dilemma of explaining vaccine technology to patients and the general public.

Wall Street analysts expect Moderna (MRNA) to post quarterly loss of $2.92 per share in its upcoming report, which indicates a year-over-year increase of 4.9%. Revenues are expected to be $126.98 ...

Amid a multi-year surge in vaccine misinformation sparked by the Covid-19 pandemic, social media posts claimed that the ...

In the early days of the COVID-19 pandemic, Moderna (NASDAQ: MRNA) was a top performer, from both a share-price and an ...

Moderna faces challenges with respiratory vaccine sales and strong competition. Click here to read an analysis of MRNA stock ...

First discovered in the 1960s, mRNA is present in all living things and carries instructions from DNA to protein-making ...

Furthering its goal to grow the reach of its mRNA vaccines and guard against future pandemics, Moderna cleared a key ...

Sunshine Biopharma (SBFM) has completed additional studies on orthotopic human tumor models in mice confirming its K1.1 mRNA Lipid Nanoparticle product as a novel therapeutic agent for human ...

The scope of the report covers detailed information regarding the major factors, such as drivers, challenges, opportunities, and restraints influencing the growth of the mRNA synthesis and ...

Southern RNA is an Australian CDMO specialising in producing nucleic acid products that support the clinical development of ...

Familiar vaccine misinformation resurfaces in a Facebook video, which claims that mRNA vaccines change people’s genes. There is no factual basis for this claim.